The Caris Precision Oncology Alliance™ (POA) convenes the brightest minds in oncology, cancer care, clinical research, and drug development. The vision statement of the POA is to build the best-in-class collaborative research network focusing on precision oncology to identify predictive and prognostic markers that help in improving the outcomes and clinical care of patients with cancer. The POA aims to deliver molecular science solutions to promote clinical trials that cultivate combined clinical-genomic data and collaborative research to advance the science of cancer care. The alliance is comprised of a growing network of leading cancer centers from across the country that demonstrate a commitment to precision medicine and work collaboratively to:
It’s important for oncologists and patients to know that their data is available to them for analysis. Our database of clinical outcomes is populated with anonymized data from POA member institutions and from commercially available data. This continuous feedback loop between finding new biomarkers and interpreting their significance, provides insights for drug developers, which ultimately feeds back into our system and directly helps patients.
The Caris Precision Oncology Alliance™ is focused on collecting the latest scientific developments in genomics in order to help ensure the availability of individualized data to oncologists and patients and to further advance the integration of molecular profiling into all aspects of cancer care .”
Chadi Nabhan, MD, MBA, FACP
Chairman
Precision Oncology Alliance
In addition to creating a thought leadership network to develop best practices and guidelines for integrating molecular profiling into patient treatment management, POA members:
Executive Committee
The Caris Precision Oncology Alliance™ (POA) Executive Committee establishes appropriate molecular testing principles to serve as guidelines for the consistent application of tumor profiling across the oncology community. The Executive Committee facilitates collaborative research studies across the POA and coordinates outcome tracking initiatives to generate and document additional medical evidence for the appropriate use and impact of profiling. The Executive Committee of the POA serves as a resource to Caris leadership helping to drive research strategy and direction.
Chairman, Precision Oncology Alliance
Chief, Division Hematology and Oncology, Department of Medicine, Professor of Medicine and Oncology, Georgetown University
Associate Center Director for Translational Sciences,
Karmanos Cancer Institute
Associate Director for Clinical Research, USC Norris Comprehensive Cancer Center
Deputy Director,
University of Cincinnati Cancer Institute and The Barrett Cancer Center
Associate Dean for Oncologic Sciences, Brown University
Executive Director, University of Puerto Rico Comprehensive Cancer Center
Director, University of Texas, San Antonio, MD Anderson Center
Professor and Chair
Department of Hematology and Medical Oncology
Emory University
POA Tumor Groups
The POA Tumor Groups identify leadership opportunities, author publications, and develop protocols.
Antoinette Tan, MD, MHS
Chief of Breast Medical Oncology and Co-director of the Phase 1 Program,
Carolinas HealthCare System, Levine Cancer Institute
David Ashley, MBBS, PhD
Professor of Neurosurgery,
Duke University
Geoff Gibney, MD
Co-leader, Melanoma Disease Group,
Lombardi Comprehensive Cancer Center and MedStar Cancer Network
Anthony Shields, MD, PhD
Associate Center Director, Clinical Sciences, and Program Leader for Molecular Imaging, Karmanos Cancer Center Institute
Elisabeth Heath, MD
Associate Center Director for Translational Sciences,
Karmanos Cancer Institute
Jubilee Brown, MD
Professor and Associate Director of Gynecologic Oncology,
Carolinas HealthCare System, Levine Cancer Institute
Jay Yang, MD
Assistant Professor of Hematology and Oncology, Member of the Malignant Hematology Multidisciplinary Team, Karmanos Cancer Institute
Andrew Evens, DO, MSc, FACP
Associate Director for Clinical Services and Director of the Lymphoma Program,
Rutgers Cancer Institute of NJ
Saad Z. Usmani, MD
Director of the Plasma Cell Disorder program and the Director of Clinical Research in Hematologic Malignancies,
Levine Cancer Institute
Sonika Dahiya, MD
Associate Professor,
Washington University
Valerie Brown, MD, PhD
Professor, Department of Pediatrics
Division of Hematology and Oncology
Penn State University
Jonathan Trent, MD, PhD
Associate Director for Clinical Research,
Sylvester Comprehensive Cancer Center at University of Miami
Stephen Liu, MD
Associate Professor of Medicine, Director of Thoracic Oncology,
Georgetown Lombardi Comprehensive Cancer Center
Wafik El-Deiry, MD, PhD, FACP
Associate Dean for Oncology,
Brown University
POA Pathology Group
Sonika Dahiya, MD
Associate Professor,
Washington University
Yihong Wang, MD, PhD
Associate Professor of Pathology and Laboratory Medicine,
Brown University
Giselle Y. Lopez, MD, PhD
Assistant Professor,
The Preston Tisch Brain Tumor Center at Duke
Thuy Phung, MD, PhD
Associate Professor of Pathology,
University of South Alabama
Evgeny Yakirevich, MD
Professor of Pathology and Laboratory Medicine, Brown University
Rouba Ali-Fehmi, MD
Professor and Vice Chair, Pathology,
Wayne State University
Sam Wei, MD, PhD
Assistant Professor, Department of Pathology, Fox Chase Cancer Center
Olga Weinberg, MD
Associate Professor, Director of Fellowships, University of Texas Southwestern
Rebecca Chernock, MD
Associate Professor, Pathology & Immunology,
Washington University
Andrew E. Rosenberg, MD
Professor, Vice Chair, Director of Bone and Soft Tissue Pathology,
University of Miami
Sanja Dacic, MD, Phd
Professor of Pathology, University of Pittsburgh Medical Center
David Braxton, MD
Molecular Genetic Pathologist,
Hoag
The Caris Precision Oncology Alliance™ consists of leading cancer centers around the world that are committed to precision medicine and work collaboratively to advance the delivery of molecular testing and establish standards of care for profiling solid tumors.
Every day, new discoveries confirm the increasing and important role biomarker analysis and tumor profiling have in personalized cancer care. We contribute to the body of research in oncology to advance the understanding of molecular science and further enable the delivery of precision medicine.